• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, November 17, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Study Evaluates Tirofiban Safety in Elderly Acute Ischemic Stroke Patients

by
November 7, 2026
in Health
Reading Time: 3 mins read
0
Study Evaluates Tirofiban Safety in Elderly Acute Ischemic Stroke Patients

Study Evaluates Tirofiban Safety in Elderly Acute Ischemic Stroke Patients

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

In an exploratory retrospective study, treatment with the glycoprotein IIb/IIIa receptor antagonist tirofiban in elderly patients aged 75 years and older with acute ischemic stroke was not associated with a statistically significant increase in bleeding events or mortality in unadjusted comparisons. The single-center investigation, published in BMC Neurology by researchers including Liujie Yin, Hongke Wang, Mingzhe Li, Luchao Jing, and Shize Li, examined whether safety and functional outcomes differed between elderly and younger patients receiving the medication.

Although tirofiban is established as a safe and effective treatment for acute ischemic stroke, clinical evidence defining its safety and therapeutic efficacy in very elderly populations aged 75 and above has remained limited. To address this question, investigators reviewed records from 150 acute ischemic stroke patients treated at Zhengzhou Central Hospital between January 2022 and June 2024. The study cohort was divided into an elderly group comprising 46 patients aged 75 years or older and a non-elderly group comprising 104 patients under 75 years of age.

Baseline characteristics were gathered from both cohorts, and researchers evaluated functional recovery and neurological deficits before treatment, after treatment, at discharge, and at 90 days. The primary efficacy outcome was the change from baseline to 90 days in National Institutes of Health Stroke Scale (NIHSS) and modified Rankin Scale (mRS) scores. Neurological improvement was comparable across cohorts, with no statistically significant differences observed in 90-day score changes. The median change in NIHSS score from baseline to 90 days was 4.0 points in the elderly group versus 3.0 points in the non-elderly group (P = 0.663), while both groups exhibited an identical median change of 1.0 point on the mRS (P = 0.199).

In an exploratory subgroup analysis restricted to patients with an onset-to-treatment time of less than eight hours, both the elderly and non-elderly groups demonstrated similar improvements on NIHSS and mRS metrics at 90 days. Drug safety evaluations assessed comparative mortality and post-medication bleeding complications, which included moderate to severe symptomatic intracranial hemorrhage, asymptomatic intracranial hemorrhage, gum bleeding, skin and mucous membrane bleeding, gastrointestinal bleeding, urinary bleeding, and other bleeding events.

Safety assessments revealed that no deaths occurred in either group during the study. The incidence of any bleeding events was 19.6 percent in the elderly group compared with 9.6 percent in the non-elderly group, a difference that did not reach statistical significance (P = 0.091). However, the authors noted that this numerically higher bleeding rate warrants caution and confirmation in larger studies. The investigators emphasized that due to the retrospective design, small elderly sample size, and unadjusted baseline differences between groups, these findings do not establish equivalence or definitive safety and efficacy, concluding that while age alone should not necessarily preclude tirofiban use, prospective randomized studies with adequate adjustment for confounders are needed.

Subject of Research: Safety and functional outcomes of tirofiban in elderly acute ischemic stroke patients

Article Title: Safety of GPâ…¡b/â…¢a receptor antagonist tirofiban in elderly patients with acute ischemic stroke

Article References: Yin, L., Wang, H., Li, M., Jing, L., & Li, S. (2026). Safety of GPâ…¡b/â…¢a receptor antagonist tirofiban in elderly patients with acute ischemic stroke. BMC Neurology. https://doi.org/10.1186/s12883-026-05545-6

Image Credits: AI Generated

DOI: 10.1186/s12883-026-05545-6

Keywords: tirofiban, acute ischemic stroke, elderly patients, stroke treatment, bleeding risk, neurology, NIHSS, modified Rankin Scale, Safety, receptor, antagonist, elderly

News Source: Cassandra Pierce. (November 7, 2026). Study Evaluates Tirofiban Safety in Elderly Acute Ischemic Stroke Patients. Scienmag.

Tags: acute ischemic strokeantagonistbleeding riskelderlyElderly Patientsmodified Rankin ScaleneurologyNIHSSreceptorsafetystroke treatmenttirofiban
Share12Tweet7Share2ShareShareShare1

Related Posts

Precision Immunotherapy Targets Sepsis’s Dynamic and Biphasic Immune Response

Precision Immunotherapy Targets Sepsis’s Dynamic and Biphasic Immune Response

November 17, 2026
Forensic Linguistics Cannot Settle Disputed Suicide Cases Without Independent Corroborating Evidence

Forensic Linguistics Cannot Settle Disputed Suicide Cases Without Independent Corroborating Evidence

November 17, 2026

SFTS Case Fatality in Changqing Remained Unchanged Across Intervention Phases

November 17, 2026

Retirement In China Improves Rural Men’s Cognition But Not Urban Men’s Health

November 17, 2026

POPULAR NEWS

  • Sesbania Hay Replacement Modifies Lamb Muscle Lipids and Meat Flavor Precursors

    Sesbania Hay Replacement Modifies Lamb Muscle Lipids and Meat Flavor Precursors

    29 shares
    Share 12 Tweet 7
  • Human Guided Knowledge Fusion Enhances Industrial Fault Diagnosis Graphs and Retrieval

    29 shares
    Share 12 Tweet 7
  • Geostatistical Kriging Maps Regional Ionospheric Storm Anomalies Across Türkiye

    29 shares
    Share 12 Tweet 7
  • Pediatric Mononucleosis Study Finds Exploratory Links Between Viral Load and Laboratory Measures

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Precision Immunotherapy Targets Sepsis’s Dynamic and Biphasic Immune Response

Forensic Linguistics Cannot Settle Disputed Suicide Cases Without Independent Corroborating Evidence

SFTS Case Fatality in Changqing Remained Unchanged Across Intervention Phases

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.